Considering Neoadjuvant Chemotherapy Options in Bladder Cancer
In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.
Video Player is loading.
In this peer-to-peer discussion, Petros Grivas, MD, PhD, of the Cleveland Clinic in Cleveland, Ohio, and Phillip L. Palmbos, MD, PhD, of the University of Michigan in Ann Arbor, Michigan, examine the role of neoadjuvant chemotherapy in bladder cancer, weighing the various trial data that guide these treatment decisions, with considerations for patient comorbidities.
Financial Disclosure:Dr. Grivas is a consultant for Genentech.
Recent Videos
Making a ‘World of Difference’ Via Multidisciplinary Care in GI, GU Cancers
Reviewing QOL Strategies/Considerations Following Bladder Cancer Surgery
Outlining Risk Factor Identification and Mitigation in Bladder Cancer
How a Radiation Oncologist Answers Patient Questions with Research
There Is Excitement and Advances in SBRT Treatment For RCC
Radiation Oncology in Prostate Cancer Is Advancing Thanks to Technology and Time
Strong Collaboration is Essential for Radiation Oncologists and Other Experts
Perioperative Durvalumab Yields Improved Efficacy in NIAGARA Regimen
The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
Durvalumab/Chemotherapy Deserving of Consideration in Neoadjuvant MIBC
